Work

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Year: 2010

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-009-9381-y

Authors: Joleen Hubbard, Charles Erlichman, David O. Toft, Rui Qin, Bridget A. Stensgard, Sara Felten, Cynthia Ten Eyck, Gretchen Batzel, S. Percy Ivy, Paul Haluska

Institutions: Mayo Clinic, National Cancer Institute

Language: English

Topic: Heat shock proteins research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1828094709, G6431364103, G7114658202, Mayo Clinic Comprehensive Cancer Center Support Grant, Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic, Mayo Clinic Ovarian Cancer SPORE

OpenAlex ID: W2029761703

FWCI: 2.083

Cites: 30

Cited by: 37

Related to: 10